Researchers have found that an anti-parasitic drug already available around the world can kill the novel coronavirus grown in cell cultures within 48 hours, an advance that may lead to the development and trial of a new clinical therapy for COVID-19.
According to the study, published in the journal Antiviral Research, the drug, Ivermectin, stopped the virus, SARS-CoV-2, from growing in cell culture within 48 hours.
“We found that even a single dose could essentially remove all viral RNA by 48 hours and that even at 24 hours there was a really significant reduction in it,” said study co-author Kylie Wagstaff from Monash University in Australia.
The scientists said Ivermectin is an approved antiparasitic drug that has also been shown to be effective in vitro against a broad range of viruses including HIV, Dengue, Influenza and Zika virus.
However, Wagstaff cautioned that the tests conducted in the study were in vitro and that trials needed to be carried out in people.
“Ivermectin is very widely used and seen as a safe drug. We need to figure out now whether the dosage you can use it at in humans will be effective – that’s the next step,” Wagstaff said.
“In times when we’re having a global pandemic and there isn’t an approved treatment, if we had a compound that was already available around the world then that might help people sooner,” she said.
Although the mechanism by which Ivermectin works on the virus is not known, the scientists said it is likely, based on its action in other viruses, that it works to stop the virus ‘dampening down’ the host cells’ ability to clear it.
“As the virologist who was part of the team who were first to isolate and share SARS-COV2 outside of China in January 2020, I am excited about the prospect of Ivermectin being used as a potential drug against COVID-19,” said Leon Caly, study co-author from the Royal Melbourne Hospital in Australia.
The scientists further cautioned that the use of Ivermectin to combat COVID-19 would depend on the results of future pre-clinical testing and ultimately clinical trials.